IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence

Inclusion Criteria: * Have a diagnosis of ovarian, fallopian tube, or primary peritoneal cancer who have received systemic chemotherapy including platinum-based chemotherapy * Have a cancer antigen 125 (CA-125) that normalized after first-line therapy * CA-125 increased to more than twice the upper limit of normal or two times the nadir value after most recent second or later line of treatment * Have no measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Ascites and pleural effusions are not measurable disease, if asymptomatic * All patients who are having sex that can lead to pregnancy must agree to contraception for the duration of the study (end of one year follow up). Note: Acceptable methods of contraception are condoms with contraceptive foam, oral, implantable or injectable contraceptives, contraceptive patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is surgically sterilized or postmenopausal * Have estimated life expectancy of at least 3 months * Be willing and able to provide written informed consent/assent for the trial * Be ≥ 18 years of age on day of signing informed consent * Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) performance scale * White blood cell (WBC) ≥ 3000/mm\^3 (performed within 14 days of treatment initiation) * Hemoglobin (Hgb) ≥ 10 g/dl (performed within 14 days of treatment initiation) * Hematocrit (Hct) ≥ 28% (performed within 14 days…